Display options
Cite
Ortendahl JD, Pulgar SJ, Mirakhur B, et al. Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals. Clinicoecon Outcomes Res. 2017;9:495-503doi: 10.2147/CEOR.S140866.
Ortendahl, J. D., Pulgar, S. J., Mirakhur, B., Cox, D., Bentley, T. G., & Phan, A. T. (2017). Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals. ClinicoEconomics and outcomes research : CEOR, 9495-503. https://doi.org/10.2147/CEOR.S140866
Ortendahl, Jesse D, et al. "Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals." ClinicoEconomics and outcomes research : CEOR vol. 9 (2017): 495-503. doi: https://doi.org/10.2147/CEOR.S140866
Ortendahl JD, Pulgar SJ, Mirakhur B, Cox D, Bentley TG, Phan AT. Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals. Clinicoecon Outcomes Res. 2017 Aug 16;9:495-503. doi: 10.2147/CEOR.S140866. eCollection 2017. PMID: 28860831; PMCID: PMC5566387.
Copy Download .nbib Format: NLM
Share it on

Clinicoecon Outcomes Res. 2017 Aug 16;9:495-503. doi: 10.2147/CEOR.S140866. eCollection 2017.

Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals.

ClinicoEconomics and outcomes research : CEOR

Jesse D Ortendahl, Sonia J Pulgar, Beloo Mirakhur, David Cox, Tanya Gk Bentley, Alexandria T Phan

Affiliations

  1. Health Economics, Partnership for Health, LLC, Beverly Hills, CA, USA.
  2. Health Economics and Outcomes Research, Ipsen Biopharmaceuticals, Basking Ridge, NJ, USA.
  3. Medical Affairs, Oncology, Ipsen Biopharmaceuticals, Basking Ridge, NJ, USA.
  4. GI Medical Oncology, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.

PMID: 28860831 PMCID: PMC5566387 DOI: 10.2147/CEOR.S140866

Abstract

OBJECTIVE: With the introduction of new therapies, hospitals have to plan spending limited resources in a cost-effective manner. To assist in identifying the optimal treatment for patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors, budget impact modeling was used to estimate the financial implications of adoption and diffusion of somatostatin analogs (SSAs).

PATIENTS AND METHODS: A hypothetical cohort of 500 gastroenteropancreatic neuroendocrine tumor patients was assessed in an economic model, with the proportion with metastatic disease treated with an SSA estimated using published data. Drug acquisition, preparation, and administration costs were based on national pricing databases and published literature. Octreotide dosing was based on published estimates of real-world data, whereas for lanreotide, real-world dosing was unavailable and we therefore used the highest indicated dosing. Alternative scenarios reflecting the proportion of patients receiving lanreotide or octreotide were considered to estimate the incremental budget impact to the hospital.

RESULTS: In the base case, 313 of the initial 500 gastroenteropancreatic neuroendocrine tumor patients were treated with an SSA. The model-predicted per-patient cost was US$83,473 for lanreotide and US$89,673 for octreotide. With a hypothetical increase in lanreotide utilization from 5% to 30% of this population, the annual model-projected hospital costs decreased by US$488,615. When varying the inputs in one-way sensitivity analyses, the results were most sensitive to changes in dosing assumptions.

CONCLUSION: Results suggest that factors beyond drug acquisition cost can influence the budget impact to a hospital. When considering preparation and administration time, and real-world dosing, use of lanreotide has the potential to reduce health care expenditures associated with metastatic gastroenteropancreatic neuroendocrine tumor treatments.

Keywords: costs; health economics; lanreotide; model; oncology; real-world evidence

Conflict of interest statement

Disclosure JDO and TGKB are employees of Partnership for Health Analytic Research, LLC and were paid by Ipsen Biopharmaceuticals to conduct this study. SJP, BM, and DC are employees of Ipsen Biopharma

References

  1. Cancer. 2015 Feb 15;121(4):589-97 - PubMed
  2. Value Health. 2014 Jan-Feb;17(1):5-14 - PubMed
  3. J Clin Oncol. 2008 Jun 20;26(18):3063-72 - PubMed
  4. N Engl J Med. 2014 Jul 17;371(3):224-33 - PubMed
  5. J Clin Oncol. 2009 Oct 1;27(28):4656-63 - PubMed
  6. Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):835-42 - PubMed
  7. Endocr Relat Cancer. 2016 Mar;23 (3):191-9 - PubMed
  8. Pancreas. 2013 Jul;42(5):878-82 - PubMed
  9. N Engl J Med. 1982 Aug 5;307(6):356-8 - PubMed
  10. Ann Oncol. 2008 Oct;19(10):1727-33 - PubMed
  11. J Clin Oncol. 1987 Oct;5(10):1502-22 - PubMed
  12. BMJ. 2006 Mar 18;332(7542):637-8 - PubMed
  13. Dig Liver Dis. 2016 May;48(5):552-558 - PubMed
  14. Curr Oncol Rep. 2016 Jan;18(1):7 - PubMed
  15. N Engl J Med. 2017 Jan 12;376(2):125-135 - PubMed
  16. Med Devices (Auckl). 2012;5:103-9 - PubMed
  17. Case Rep Oncol. 2014 Mar 05;7(1):155-63 - PubMed
  18. J Histochem Cytochem. 1969 May;17(5):303-13 - PubMed
  19. Crit Rev Oncol Hematol. 2016 Feb;98 :264-74 - PubMed
  20. Oncologist. 2014 Sep;19(9):930-6 - PubMed
  21. Eur J Radiol. 2006 Jun;58(3):480-4 - PubMed
  22. World J Gastroenterol. 2013 Apr 21;19(15):2348-54 - PubMed
  23. Neuroendocrinology. 2017;104(1):26-32 - PubMed
  24. J Adv Nurs. 2007 Jun;58(6):552-6 - PubMed
  25. Value Health. 2007 Sep-Oct;10(5):336-47 - PubMed
  26. Health Aff (Millwood). 2014 Jan;33(1):95-102 - PubMed
  27. Lancet Oncol. 2008 Jan;9(1):61-72 - PubMed

Publication Types